Druggable targets for sudden cardiac death prevention: lessons from the past and strategies for the future

Current Opinion in Pharmacology

Volumn 9, Issue 2, 2009, Pages 146-153

  Clements Jewery, Hugh ^b   Andrag, Ellen ^a   Curtis, Michael J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b WEST VIRGINIA SCHOOL OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CANNABINOID; DEXANABINOL; FLECAINIDE; PENICILLIN G; RANOLAZINE; SODIUM CHANNEL; SOTALOL;

ARRHYTHMOGENESIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; HEART ARRHYTHMIA; HEART CONDUCTION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE ISCHEMIA; HEART VENTRICLE FIBRILLATION; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SUDDEN DEATH;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; CLINICAL TRIALS AS TOPIC; DEATH, SUDDEN, CARDIAC; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; GAP JUNCTIONS; HUMANS; ION CHANNELS; MYOCARDIAL ISCHEMIA; VENTRICULAR FIBRILLATION;

EID: 62249188074     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2008.12.005     Document Type: Review

References (75)

1. Campbell R.W. Treatment and prophylaxis of ventricular arrhythmias in acute myocardial infarction. Am J Cardiol 52 (1983) 55C-59C. This paper was one of the first to properly put the importance of VF in humans in acute ischaemia in context as a major cause of lethality in ischaemic heart disease.
2. Rosamond W., Flegal K., Furie K., Go A., Greenlund K., Haase N., Hailpern S.M., Ho M., Howard V., Kissela B., Kittner S., et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117 (2008) e25-146
3. Huikuri H.V., Castellanos A., and Myerburg R.J. Sudden death due to cardiac arrhythmias. N Engl J Med 345 (2001) 1473-1482. This paper identifies the relative prevalence of cardiac health and disease (heart failure) in sudden cardiac death victims, illustrating the important fact that the largest cohort of victims by far is the cohort with little or no pre-existent cardiac disease. It concludes that cardiac heritable abnormalities may explain the risk whereas we suggest that it is the risk of acute ischaemia (i.e., a coronary vascular pathology) that accounts for the findings.
4. Zipes D.P., and Wellens H.J. Sudden cardiac death. Circulation 98 (1998) 2334-2351
5. Billman G.E. A comprehensive review and analysis of 25 years of data from an in vivo canine model of sudden cardiac death: Implications for future anti-arrhythmic drug development. Pharmacol Ther 111 (2006) 808-835. This paper reviews one of the more clinically relevant models for detecting possible VF suppressing drugs, a model with a large database for interrogation.
6. Curtis M.J. Characterisation, utilisation and clinical relevance of isolated perfused heart models of ischaemia-induced ventricular fibrillation. Cardiovasc Res 39 (1998) 194-215. This paper reviews one of the simpler and more high-throughput models for evaluating VF preventive drugs and ancillary pharmacology. It also proposes ways of integrating model ease of use with clinical relevance and provides a large drug database and a comparison with other models.
7. Kaumann A.J., and Aramendia P. Prevention of ventricular fibrillation induced by coronary ligation. J Pharmacol Exp Therap 164 (1968) 326-332. One of the first papers to describe a drug that can prevent VF and improve survival in a large animal model of ischaemia-induced VF.
8. Smith T.W., and Cain M.E. Sudden cardiac death: epidemiologic and financial worldwide perspective. J Interv Card Electrophysiol 17 (2006) 199-203
9. CAST. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 321 (1989) 406-412. The first body blow to anti-VF drug discovery-a catastrophic clinical trial that revealed an increase in death in drug-treated patients.
10. Waldo A.L., Camm A.J., deRuyter H., Friedman P.L., MacNeil D.J., Pauls J.F., Pitt B., Pratt C.M., Schwartz P.J., and Veltri E.P. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD investigators. Survival with oral d-sotalol. Lancet 348 (1996) 7-12. The second (and apparently lethal) body blow to anti-VF drug discovery. A second class of ion-channel-targeting drugs increased death following myocardial infarction in patients.
11. Pratt C.M., and Moye L.A. The cardiac arrhythmia suppression trial: background, interim results and implications. Am J Cardiol 65 (1990) 20B-29B. Evaluation of the CAST study (see reference above) revealed uncertainty. The uncertainty has left industry unwilling to engage in anti-VF drug discovery. The status quo prevails today, to all our detriment.
12. Echt D.S., Liebson P.R., Mitchell L.B., Peters R.W., Obias-Manno D., Barker A.H., Arensberg D., Baker A., Friedman L., Greene H.L., et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324 (1991) 781-788
13. Farkas A., and Curtis M.J. Limited antifibrillatory effectiveness of clinically relevant concentrations of class I antiarrhythmics in isolated perfused rat hearts. J Cardiovasc Pharmacol 39 (2002) 412-424. Lack of benefit of clinically relevant concentrations of Class 1 antiarrhythmics against ischaemia-induced VF in an animal model reiterates the findings of the CAST study. Perhaps this study should have been carried out in the mid 1980s rather than 2002.
14. Curtis M.J. Torsades de pointes: arrhythmia, syndrome, or chimera? A perspective in the light of the Lambeth Conventions. Cardiovasc Drugs Therapy 5 (1991) 191-200
15. Shor A., Libby P., Ridker P.M., and Maseri A. Atherosclerosis: lipid infiltration or Chlamydia pneumoniae infection?* Response. Circulation 106 (2002) e135-136
16. Yong S.L., Xu R., McLarnon J.G., Zolotoy A.B., Beatch G.N., and Walker M.J.A. RSD1000: a novel antiarrhythmic agent with increased potency under acidic and high-potassium conditions. J Pharmacol Exp Ther 289 (1999) 236-244
17. Roy D., Pratt C.M., Torp-Pedersen C., Wyse D.G., Toft E., Juul-Moller S., Nielsen T., Rasmussen S.L., Stiell I.G., Coutu B., Ip J.H., et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 117 (2008) 1518-1525
18. Curtis M.J. Calcium antagonists and coronary artery disease: an opportunity missed?. J Neural Transm Suppl 31 (1990) 17-38
19. Curtis M.J., MacLeod B.A., and Walker M.J. Antiarrhythmic actions of verapamil against ischaemic arrhythmias in the rat. Br J Pharmacol 83 (1984) 373-385
20. Billman G.E. Effect of calcium channel antagonists on susceptibility to sudden cardiac death: protection from ventricular fibrillation. J Pharmacol Exp Ther 248 (1989) 1334-1342
21. Farkas A., Qureshi A., and Curtis M.J. Inadequate ischaemia-selectivity limits the antiarrhythmic efficacy of mibefradil during regional ischaemia and reperfusion in the rat isolated perfused heart. Br J Pharmacol 128 (1999) 41-50. Class 4 antiarrhythmics are effective in preventing experimental ischaemia-induced VF but only at concentrations that dilate blood vessels. This paper is important not only because it explains clinical findings but also because it nevertheless confirms proof of concept-ventricular L channel blockade in the ischaemic region can suppress VF. Unfortunately we do not yet have a drug that possesses the required selectivity for the ischaemic milieu.
22. Curtis M.J., and Walker M.J. The mechanism of action of calcium antagonists on arrhythmias in early myocardial ischaemia: studies with nifedipine and DHM9. Br J Pharmacol 94 (1988) 1275-1286
23. Gupta A., Lawrence A.T., Krishnan K., Kavinsky C.J., and Trohman R.G. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J 153 (2007) 891-899
24. Saint D.A. The cardiac persistent sodium current: an appealing therapeutic target?. Br J Pharmacol 153 (2007) 1133-1142. A new target logically explained.
25. + current during cardiac ischemia and hypoxia. J Cardiovasc Electrophysiol 17 Suppl. 1 (2006) S96-S103
26. +] in ventricular myocytes. Am J Physiol 277 (1999) H1817-H1822
27. Morrow D.A., Scirica B.M., Karwatowska-Prokopczuk E., Murphy S.A., Budaj A., Varshavsky S., Wolff A.A., Skene A., McCabe C.H., and Braunwald E. For the M-TTI: effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 297 (2007) 1775-1783
28. Antzelevitch C., Belardinelli L., Zygmunt A.C., Burashnikov A., Di Diego J.M., Fish J.M., Cordeiro J.M., and Thomas G. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110 (2004) 904-910
29. Clarke T.C., Thomas D., Petersen J.S., Evans W.H., and Martin P.E. The antiarrhythmic peptide rotigaptide (ZP123) increases gap junction intercellular communication in cardiac myocytes and HeLa cells expressing connexin 43. Br J Pharmacol 147 (2006) 486-495
30. Hennan J.K., Swillo R.E., Morgan G.A., Keith Jr. J.C., Schaub R.G., Smith R.P., Feldman H.S., Haugan K., Kantrowitz J., Wang P.J., Abu-Qare A., et al. Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs. J Pharmacol Exp Ther 317 (2006) 236-243
31. Harris A.S., Bisteni A., Russell R.A., Brigham J.C., and Firestone J.E. Excitatory factors in ventricular tachycardia resulting from myocardial ischaemia. Potassium as a major excitant. Science 119 (1954) 200-203. A classic paper. These data introduced the concept of endogenous chemical mediation of VF.
32. Curtis M.J., Pugsley M.K., and Walker M.J. Endogenous chemical mediators of ventricular arrhythmias in ischaemic heart disease. Cardiovasc Res 27 (1993) 703-719. A modern day elaboration of the concept of endogenous chemical mediation of VF, with proposals for identifying which mediators are sufficient and which are necessary for VF to occur (and hence which represent targettable mechanisms).
33. + reveals that ischaemic arrhythmias is caused by independent effects of endogenous 'mediators' facilitated by interactions, and moderated by paradoxical antagonism. Br J Pharmacol 142 (2004) 352-366. A very depressing paper. It suggests that pathophysiological reserve is not the only difficulty in identifying specific targets for VF suppression. It also suggests that the way mediators interact is highly complex, and the outcome of blocking the effects of one mediator may be the opposite of what may have been anticipated from the study of the effects of the mediator in isolation.
34. Hearse D.J., Humphrey S.M., Feuvray D., and De Leiris J. A biochemical and ultrastructural study of the species variation in myocardial cell damage. J Mol Cell Cardiol 8 (1976) 759-778
35. + activity in swine. Circulation 61 (1980) 768-778
36. + increase and noradrenaline release as possible cause of early arrhythmias following acute coronary artery occlusion in pigs. J Mol Cell Cardiol 12 (1980) 579-593
37. + during global ischaemia in isolated rat hearts. J Mol Cell Cardiol 22 (1990) 1259-1272
38. Curtis M.J. The rabbit dual coronary perfusion model: a new method for assessing the pathological relevance of individual products of the ischaemic milieu: role of potassium in arrhythmogenesis. Cardiovasc Res 25 (1991) 1010-1022
39. Clements-Jewery H., and Curtis M.J. Biochemical mediators of ventricular arrhythmias in ischaemic heart disease. In: Pugsley M.K. (Ed). Cardiac Drug Development Guide (2003), Humana Press, Tottowa, NJ, USA 203-226. An interrogation of possible mediators of ischaemia-induced VF, updated.
40. Curtis M.J., and Hearse D.J. Ischaemia-induced and reperfusion-induced arrhythmias differ in their sensitivity to potassium: implications for mechanisms of initiation and maintenance of ventricular fibrillation. J Mol Cell Cardiol 21 (1989) 21-40
41. + changes in the functioning heart under conditions of ischaemia and congestion. Am J Physiol 123 (1938) 579-593
42. Morena H., Janse M.J., Fiolet J.W., Krieger W.J., Crijns H., and Durrer D. Comparison of the effects of regional ischemia, hypoxia, hyperkalemia, and acidosis on intracellular and extracellular potentials and metabolism in the isolated porcine heart. Circ Res 46 (1980) 634-646
43. Harris A.S., Toth L.A., and Hooey T.E. Arrhythmic and antiarrhythmic effects of sodium, potassium, and calcium salts and of glucose injected into coronary arteries of infarcted and normal hearts. Circ Res 6 (1958) 570-579
44. Janse M.J., and Kleber A.G. Electrophysiological changes and ventricular arrhythmias in the early phase of regional myocardial ischemia. Circ Res 49 (1981) 1069-1081
45. Corr P.B., Creer M.H., Yamada K.A., Saffitz J.E., and Sobel B.E. Prophylaxis of early ventricular fibrillation by inhibition of acylcarnitine accumulation. J Clin Invest 83 (1989) 927-936. Identification of a promising and ischaemia-selective target for VF suppression. What happened in the intervening 20 years, we wonder?
46. Bril A. Cellular mechanisms of cardiac arrhythmias in the ischemic and reperfused heart. In: Karmazyn M. (Ed). Myocardial Ischemia: Mechanisms, Reperfusion, Protection (1996), Birkhäuser Publishing Ltd. 135-153
47. Mancuso D.J., Abendschein D.R., Jenkins C.M., Han X., Saffitz J.E., Schuessler R.B., and Gross R.W. Cardiac ischemia activates calcium-independent phospholipase A2beta, precipitating ventricular tachyarrhythmias in transgenic mice: rescue of the lethal electrophysiologic phenotype by mechanism-based inhibition. J Biol Chem 278 (2003) 22231-22236. The lipid model of VF initiation (see Corr above) is alive. Is it well? Apparently.
48. Antman E.M., Lau J., Kupelnick B., Mosteller F., and Chalmers T.C. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. JAMA 268 (1992) 240-248. The first comprehensive assessment of which drugs actually reduce death following myocardial infarction in humans. This paper clearly shows that lidocaine is ineffective, yet lidocaine remained a first line acute intervention around the world for the following decade. This illustrates the conservative nature of medicine and the slow progress in this area. Lidocaine may not work, but at least it is safe, and this appears to be the only justification for its use. Odd and depressing.
49. Schömig A., Dart A.M., Dietz R., Mayer E., and Kubler W. Release of endogenous catecholamines in the ischemic myocardium of the rat. Part A: Locally mediated release. Circ Res 55 (1984) 689-701
50. Cinca J., Bardaji A., and Salas-Caudevilla A. Ventricular arrhythmias and local electrograms after chronic regional denervation of the ischemic area in the pig heart. J Am Coll Cardiol 14 (1989) 225-232
51. Curtis M.J., Botting J.H., Hearse D.J., and Walker M.J.A. The sympathetic nervous system, catecholamines and ischaemia-induced arrhythmias: dependence upon serum potassium concentration. In: Brachmann J., and Schömig A. (Eds). Adrenergic System and Ventricular Arrhythmias in Myocardial Infarction (1989), Springer-Verlag, Berlin 206-219
52. Lameris T.W., de Zeeuw S., Alberts G., Boomsma F., Duncker D.J., Verdouw P.D., Veld A.J., and van Den Meiracker A.H. Time course and mechanism of myocardial catecholamine release during transient ischemia in vivo. Circulation 101 (2000) 2645-2650
53. Ko D.T., Hebert P.R., Coffey C.S., Curtis J.P., Foody J.M., Sedrakyan A., and Krumholz H.M. Adverse effects of {beta}-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. Arch Intern Med 164 (2004) 1389-1394
54. Daugherty A., Frayn K., Redfern W., and Woodward B. The role of catecholamines in the production of ischaemia-induced ventricular arrhythmias in the rat in vivo and in vitro. Br J Pharmacol 87 (1986) 265-277
55. Rochette L., Didier J., Moreau D., Bralet J., and Opie L. Role of beta-adrenoreceptor antagonism in the prevention of reperfusion ventricular arrhythmias: effects of acebutolol, atenolol, and d-propranolol on isolated working rat hearts subject to myocardial ischemia and reperfusion. Am Heart J 107 (1984) 1132-1141
56. Clements-Jewery H., Hearse D.J., and Curtis M.J. Independent contribution of catecholamines to arrhythmogenesis during evolving infarction in the isolated rat heart. Br J Pharmacol 135 (2002) 807-815
57. Clements-Jewery H., Hearse D.J., and Curtis M.J. Phase 2 ventricular arrhythmias in acute myocardial infarction: a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation. Br J Pharmacol 145 (2005) 551-564. Not all VF following acute myocardial ischaemia is caused by acute ischaemia. This review illustrates that different mechanisms are likely to be involved in VF generation during the first 24 h after myocardial infarction. This means that targets are likely to be time-dependent, requiring different drugs at different moments during the rapidly changing evolution of the infarcting milieu.
58. Yu X., Huang S., Patterson E., Garrett M.W., Kaufman K.M., Metcalf J.P., Zhu M., Dunn S.T., and Kem D.C. Proteasome degradation of GRK2 during ischemia and ventricular tachyarrhythmias in a canine model of myocardial infarction. Am J Physiol Heart Circ Physiol 289 (2005) H1960-1967
59. Krylatov A.V., Ugdyzhekova D.S., Bernatskaya N.A., Maslov L.N., Mekhoulam R., Pertwee R.G., and Stephano G.B. Activation of type II cannabinoid receptors improves myocardial tolerance to arrhythmogenic effects of coronary occlusion and reperfusion. Bull Exp Biol Med 131 (2001) 523-525
60. Ugdyzhekova D.S., Bernatskaya N.A., Stefano J.B., Graier V.F., Tam S.W., and Mekhoulam R. Endogenous cannabinoid anandamide increases heart resistance to arrhythmogenic effects of epinephrine: role of CB(1) and CB(2) receptors. Bull Exp Biol Med 131 (2001) 251-253
61. Ugdyzhekova D.S., Krylatov A.V., Bernatskaya N.A., Maslov L.N., Mechoulam R., and Pertwee R.G. Activation of cannabinoid receptors decreases the area of ischemic myocardial necrosis. Bull Exp Biol Med 133 (2002) 125-126
62. Felder C.C., Joyce K.E., Briley E.M., Glass M., Mackie K.P., Fahey K.J., Cullinan G.J., Hunden D.C., Johnson D.W., Chaney M.O., Koppel G.A., et al. LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther 284 (1998) 291-297
63. Howlett A.C. Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds. Life Sci 35 (1984) 1803-1810
64. Howlett A.C., Qualy J.M., and Khachatrian L.L. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol 29 (1986) 307-313
65. Bouaboula M., Poinot-Chazel C., Bourrie B., Canat X., Calandra B., Rinaldi-Carmona M., Le Fur G., and Casellas P. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 312 (1995) 637-641
66. Rueda D., Galve-Roperh I., Haro A., and Guzman M. The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. Mol Pharmacol 58 (2000) 814-820
67. Caulfield M.P., and Brown D.A. Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br J Pharmacol 106 (1992) 231-232
68. Gebremedhin D., Lange A.R., Campbell W.B., Hillard C.J., and Harder D.R. Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am J Physiol 276 (1999) H2085-H2093
69. Mackie K., Devane W.A., and Hille B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol Pharmacol 44 (1993) 498-503
70. Mackie K., Lai Y., Westenbroek R., and Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 15 (1995) 6552-6561
71. McAllister S.D., Griffin G., Satin L.S., and Abood M.E. Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a xenopus oocyte expression system. J Pharmacol Exp Ther 291 (1999) 618-626
72. Janse M.J. Reentrant arrhythmias. In: Fozzard H.A., Haber E., Jennings R.B., Katz A.M., and Morgan H.E. (Eds). The Heart and Cardiovascular System (1992), Raven Press, New York 2055-2094
73. Early Arrhythmias Resulting from Acute Myocardial Ischaemia (1982), Macmillan, Basingstoke, UK
74. Lab M.J. Contraction-excitation feedback in myocardium. Physiological basis and clinical relevance. Circ Res 50 (1982) 757-766
75. Gettes L.S., and Cascio W.E. Effects of acute ischaemia on cardiac electrophysiology. In: Fozzard H.A., Haber E., Jennings R.B., Katz A.M., and Morgan H.E. (Eds). The Heart and Cardiovascular System (1992), Raven Press, New York 2021-2054